Synergism from combination of cisplatin and multicentred platinums coded as DH6Cl and TH1 in the human ovarian tumour models

Medicinal Chemistry

Volumn 7, Issue 6, 2011, Pages 593-598

  Alshehri, Ali ^a   Beale, Philip ^b   Yu, Jun Qing ^a   Huq, Fazlul ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b SYDNEY CANCER CENTRE   (Australia)

Author keywords

Cisplatin; DH6Cl; Drug combination; Ovarian cancer; Synergism; TH1

Indexed keywords

3 HYDROXYPYRIDINE; CISPLATIN; LIGAND; METAL ION; NUCLEIC ACID BASE; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER RESISTANCE; CONCENTRATION RESPONSE; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG POTENTIATION; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; MOLECULAR INTERACTION; OVARY CANCER; PRIORITY JOURNAL;

EID: 80755159529     PISSN: 15734064     EISSN: 18756638     Source Type: Journal    
DOI: 10.2174/157340611797928316     Document Type: Article

References (20)

1. Lilenbaum, R.C.; Herndon, J.E. II; List, M.A.; Desch, C.; Watson, D.M.; Miller, A.A.; Graziano, S.L.; Perry, M.C.; Saville, W; Chahinian, P.; Weeks, J.C.; Holland, J.C.; Green, M.R. Single-Agent Versus Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer: The Cancer and Leukemia Group B (study 9730). J. Clin. Oncol., 2005, 23(1), 190-96. (Pubitemid 41702638)
2. Neale, M.H.; Myatt, N.; Cree, I.A.; Kurbacher, C.M.; Foss, A.J.E.; Hungerford, J.L.; Plowman, P.N. Combination chemotherapy for choroidal melanoma: Ex vivo sensitivity to treosulfan with gemcitabine or Cytosine arabinoside. British J. Cancer, 1999, 79, 1487-93. (Pubitemid 29116809)
3. Waltmire, C.N.; Alberts, D.S.; Dorr, R.T. Sequence-dependent cytotoxicity of combination chemotherapy using paclitaxel, carboplatin and bleomycin in human lung and ovarian cancer. Anti-Cancer Drugs, 2001, 12(7), 595-602. (Pubitemid 32762806)
4. Farrell, N. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents. In: Platinum-based drugs in cancer therapy. Kelland, L. R.; Farrell, N., Eds.; Humana Press: N.J. 2000; pp. 321-38.
5. 4 in ovarian cancer cell lines. ChemMedChem, 2008, 3(1), 145-51.
6. 4 where n = 4 to 7, Int. J. Pure & Appl. Chem., 2006, 1(4), 493-507.
7. 2]. Indian J. Chem., 1970, 8, 193-4.
8. Hamilton TC, Young RC and Ozols RF: Experimental model systems of ovarian cancer: Applications to the design and evaluation of new treatment approaches. Semin. Oncol., 1984, 11(3), 285-98. (Pubitemid 14013135)
9. Behrens, B.C.; Hamilton, T.C.; Masuda, H.; Grotzinger, K.R.; Whang-Peng, J.; Louie, K. G.; Knutsen, T.; McKoy, W.M.; Young, R.C.; Ozols, R.F. Characterization of a cisdiamminedichloroplatinum( II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 1987, 47(2), 414-18. (Pubitemid 17009602)
10. Masuda, H; Ozols, R.F.; Lai, G.-M.; Fojo, A.; Rothenberg, M.; Hamilton, T.C. Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum(II) in human ovarian cancer cell lines. Cancer Res., 1988, 48(20), 5713-16.
11. Holford, J.; Beale, P.J.; Boxall, F.E.; Sharp, S.Y.; Kelland, L.R. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Europ. J. Cancer, 2000, 36(15), 1984-90.
12. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol Methods, 1983, 65(1-2), 55-63. (Pubitemid 14203433)
13. Chou, T.C.; Talalay. P.L. Analysis of combined drug effects: A new look at a very old problem. Trends Pharmacol. Sci., 1983, 4(C), 450-4.
14. Chou, T.C.; Talalay, P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 1984, 22, 27-55.
15. Chou, T.C.; Talaly, P. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J. Biol. Chem. 1977, 252(18), 6438-42. (Pubitemid 8193791)
16. Alshehri, A.; Beale, P.; Yu, J.Q.; Huq, F. Synergism from combination of cisplatin and a trans-platinum compound in ovarian cancer cell lines, Anticancer Res. 2010, 4547-54.
17. Yunos, N.M. Synergism from combination between platinums and phytochemicals in ovarian cancer cell lines, PhD Thesis, The University of Sydney: Sydney Australia, 2010.
18. Mantri, Y.; Lippard, S.J.; Baik, M.H. Bifunctional Binding of Cisplatin to DNA: Why Does Cisplatin Form 1,2-Intrastrand Cross-Links with AG But Not with GA?. J. Am. Chem. Soc., 2007, 129(16), 5023-30. (Pubitemid 46651381)
19. Kostova, I. Platinum Complexes as Anticancer Agents. Recent Patents on Anti-Cancer Drug Discovery, 2006, 1, 1-22.
20. Reedijk, J. New clues for platinum antitumor chemistry: Kinetically controlled metal binding to DNA. P. Natl. Acad.Sci. USA, 2003, 100(7), 3611-16. (Pubitemid 36422584)